Uptake of biosimilars in China: a retrospective analysis of the case of trastuzumab from 2018 to 2023
Artículo
Artículo
Abstract Background The Chinese biosimilar industry has demonstrated rapid growth in recent years. Limited evidence is available about biosimilar uptake at the national level. This study aimed to assess biosimilar uptake...
LCC LCC:Public aspects of medicineIdioma Inglés
Acceso abiertoRuta libre sin proxy. Acceso recomendado cuando no hay suscripción activa.
Open Access